Artelo Biosciences, Inc. (NasdaqCM: ARTL)
Health Care · Pharmaceuticals · US
$0.72
+4.09% today · -97.4% 1Y
Artelo Biosciences, Inc. (NasdaqCM: ARTL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.30M and employs 7 people.
Over the last twelve months the share price has lost 97.4%, trading between 0.69 and 30.00.
Tweenvest scores Artelo Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
ARTL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.38
- Dividend yield
- —
- Beta (5Y)
- -0.07
- 52-week high
- $30.00
- 52-week low
- $0.69
- Avg volume (3M)
- —
- Shares outstanding
- 4.60M
- Employees
- 7
- Next earnings
- —
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
- ISIN
- US04301G7060
- Founded
- 2011
- Listed since
- Jun 21, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,234.92 | +0.10% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.25 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.27 | -0.12% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.70 | -0.03% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.52 | -0.99% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.